Docket Room.
HB 918·LA·house

PHARMACIES: Provides relative to pharmaceutical costs (OR +$153,127 GF EX See Note)

FailedFiled Feb 27, 2026
Sponsor: Jay Gallé (R)
Latest Action

Read by title, under the rules, referred to the Committee on Health and Welfare.

Mar 9, 2026

Email me when HB 918 moves

Committee action, floor votes, amendments and hearings. Free, no card, no password.

Already have an account? Track HB 918. By continuing you agree to the Terms and Privacy Policy.

Summary

The bill requires the Louisiana Department of Health to compile a list of critical prescription drugs and to collect detailed cost data from manufacturers. It forces manufacturers to report production, R&D, and marketing costs, and it mandates price disclosures in any marketing to providers. The goal is to give lawmakers and the public clearer insight into drug pricing and to curb excessive costs.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Ask about HB 918

3 free questions a day, no account

History

  1. Read by title, under the rules, referred to the Committee on Health and Welfare.
  2. Under the rules, provisionally referred to the Committee on Health and Welfare.

Sponsors

  • Jay Gallé (R) · sponsor
  • Jay Galle

Bill text

Read the official text ↗

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Share

Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.

Track this bill

Get an email when HB 918 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track HB 918 free

Or ask your AI assistant about HB 918 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice